JWM
NBIX icon

Janiczek Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Janiczek Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$12.5K Buy
+91
New +$12.5K ﹤0.01% 632

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Janiczek Wealth Management's NBIX Position: Q2 2024 in Review

Janiczek Wealth Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2024: 91 shares worth $12.5K. The stake represents ﹤0.01% of the portfolio and ranks #632 among its holdings.

594 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • Janiczek Wealth Management held 91 shares of Neurocrine Biosciences worth $12.5K as of Q2 2024.
  • Neurocrine Biosciences was a new Janiczek Wealth Management position in Q2 2024.
  • Neurocrine Biosciences made up ﹤0.01% of Janiczek Wealth Management's portfolio in Q2 2024, its #632 holding.
  • 594 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Janiczek Wealth Management's 13F filing for Q2 2024, filed 25 Jul 2024.